{"DataElement":{"publicId":"5446378","version":"1","preferredName":"Prior Therapy Description Sub Protocol Agent Type","preferredDefinition":"Type of prior therapy MATCH protocol related agents received by patient.","longName":"PrTxSbPrtSubAgtTp","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"2195107","version":"1","preferredName":"Prior Therapy Description","preferredDefinition":"information related to prior therapy.","longName":"PRIOR_TX_DESC","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"3693401","version":"1","preferredName":"Prior Therapeutic Procedure","preferredDefinition":"Earlier in time or order.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C25629:C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D743B17B-E51D-394C-E040-BB89AD4312FF","latestVersionIndicator":"Yes","beginDate":"2013-03-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2013-03-06","modifiedBy":"ONEDATA","dateModified":"2013-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177536","version":"1","preferredName":"Description ","preferredDefinition":"Description; a statement that represents something in words.","longName":"Description","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Description","conceptCode":"C25365","definition":"A written or verbal account, representation, statement, or explanation of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-51C1-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ECF1F1BC-DEFF-58A8-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"03/06/2013 - tc - Removed retired concept C15368 and replaced with NCIt concept C49236.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5446371","version":"1","preferredName":"Sub Protocol Agent Type","preferredDefinition":"MATCH protocol related agents","longName":"SbPrtSubAgtTp","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"160","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"09","valueDescription":"Palbociclib","ValueMeaning":{"publicId":"5446372","version":"1","preferredName":"Palbociclib","longName":"5446372","preferredDefinition":"09- Palbociclib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BC8F53A-0976-7871-E050-BB89AD435BF6","latestVersionIndicator":"Yes","beginDate":"2016-09-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-09-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3BC8F53A-098F-7871-E050-BB89AD435BF6","beginDate":"2016-09-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-09-05","modifiedBy":"ONEDATA","dateModified":"2016-09-05","deletedIndicator":"No"},{"value":"08","valueDescription":"Olaparib","ValueMeaning":{"publicId":"3377423","version":"1","preferredName":"Olaparib","longName":"3377423","preferredDefinition":"A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Olaparib","conceptCode":"C71721","definition":"A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DFB740-1C92-299D-E040-BB89AD430A5E","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3BC8F53A-09A3-7871-E050-BB89AD435BF6","beginDate":"2016-09-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-09-05","modifiedBy":"ONEDATA","dateModified":"2016-09-05","deletedIndicator":"No"},{"value":"07","valueDescription":"Vemurafenib","ValueMeaning":{"publicId":"3422122","version":"1","preferredName":"Vemurafenib","longName":"3422122","preferredDefinition":"An orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vemurafenib","conceptCode":"C64768","definition":"An orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC3ACCEE-3440-DAF6-E040-BB89AD433B37","latestVersionIndicator":"Yes","beginDate":"2012-03-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-03-27","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3BC8F53A-09B8-7871-E050-BB89AD435BF6","beginDate":"2016-09-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-09-05","modifiedBy":"ONEDATA","dateModified":"2016-09-05","deletedIndicator":"No"},{"value":"06","valueDescription":"Ensartinib","ValueMeaning":{"publicId":"5446373","version":"1","preferredName":"Ensartinib","longName":"5446373","preferredDefinition":"06 -Ensartinib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BC8F53A-09C3-7871-E050-BB89AD435BF6","latestVersionIndicator":"Yes","beginDate":"2016-09-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-09-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3BC8F53A-09DC-7871-E050-BB89AD435BF6","beginDate":"2016-09-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-09-05","modifiedBy":"ONEDATA","dateModified":"2016-09-05","deletedIndicator":"No"},{"value":"05","valueDescription":"Selumetinib","ValueMeaning":{"publicId":"3238481","version":"1","preferredName":"Selumetinib","longName":"3238481","preferredDefinition":"An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Selumetinib","conceptCode":"C66939","definition":"An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A41DC8A8-EBA5-0F50-E040-BB89AD436610","latestVersionIndicator":"Yes","beginDate":"2011-05-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-25","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3BC8F53A-09F0-7871-E050-BB89AD435BF6","beginDate":"2016-09-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-09-05","modifiedBy":"ONEDATA","dateModified":"2016-09-05","deletedIndicator":"No"},{"value":"04","valueDescription":"LY3023414","ValueMeaning":{"publicId":"5446374","version":"1","preferredName":"LY3023414","longName":"5446374","preferredDefinition":"04 -LY3023414","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BC8F53A-09FB-7871-E050-BB89AD435BF6","latestVersionIndicator":"Yes","beginDate":"2016-09-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-09-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3BC8F53A-0A14-7871-E050-BB89AD435BF6","beginDate":"2016-09-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-09-05","modifiedBy":"ONEDATA","dateModified":"2016-09-05","deletedIndicator":"No"},{"value":"03","valueDescription":"Tazemetostat","ValueMeaning":{"publicId":"5446375","version":"1","preferredName":"Tazemetostat","longName":"5446375","preferredDefinition":"03 -Tazemetostat","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BC8F53A-0A1E-7871-E050-BB89AD435BF6","latestVersionIndicator":"Yes","beginDate":"2016-09-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-09-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3BC8F53A-0A37-7871-E050-BB89AD435BF6","beginDate":"2016-09-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-09-05","modifiedBy":"ONEDATA","dateModified":"2016-09-05","deletedIndicator":"No"},{"value":"02","valueDescription":"Erdafitinib","ValueMeaning":{"publicId":"5446376","version":"1","preferredName":"Erdafitinib","longName":"5446376","preferredDefinition":"02 -Erdafitinib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BC8F53A-0A41-7871-E050-BB89AD435BF6","latestVersionIndicator":"Yes","beginDate":"2016-09-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-09-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3BC8F53A-0A5A-7871-E050-BB89AD435BF6","beginDate":"2016-09-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-09-05","modifiedBy":"ONEDATA","dateModified":"2016-09-05","deletedIndicator":"No"},{"value":"01","valueDescription":"LOXO-101","ValueMeaning":{"publicId":"5446377","version":"1","preferredName":"LOXO-101","longName":"5446377","preferredDefinition":"01 -LOXO-101","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BC8F53A-0A64-7871-E050-BB89AD435BF6","latestVersionIndicator":"Yes","beginDate":"2016-09-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-09-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3BC8F53A-0A7D-7871-E050-BB89AD435BF6","beginDate":"2016-09-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-09-05","modifiedBy":"ONEDATA","dateModified":"2016-09-05","deletedIndicator":"No"},{"value":"772256","valueDescription":"Palbociclib","ValueMeaning":{"publicId":"6054160","version":"1","preferredName":"Palbociclib","longName":"6054160","preferredDefinition":"772256-Palbociclib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"638A022A-E195-162B-E053-F662850A0538","latestVersionIndicator":"Yes","beginDate":"2018-01-24","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-01-24","modifiedBy":"ONEDATA","dateModified":"2018-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"638A022A-E1AD-162B-E053-F662850A0538","beginDate":"2018-01-24","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-01-24","modifiedBy":"ONEDATA","dateModified":"2018-01-24","deletedIndicator":"No"},{"value":"747856","valueDescription":"Olaparib","ValueMeaning":{"publicId":"6054161","version":"1","preferredName":"Olaparib","longName":"6054161","preferredDefinition":"747856-Olaparib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"638A022A-E1B7-162B-E053-F662850A0538","latestVersionIndicator":"Yes","beginDate":"2018-01-24","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-01-24","modifiedBy":"ONEDATA","dateModified":"2018-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"638A022A-E1CF-162B-E053-F662850A0538","beginDate":"2018-01-24","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-01-24","modifiedBy":"ONEDATA","dateModified":"2018-01-24","deletedIndicator":"No"},{"value":"761431","valueDescription":"Vemurafenib","ValueMeaning":{"publicId":"6054162","version":"1","preferredName":"Vemurafenib","longName":"6054162","preferredDefinition":"761431-Vemurafenib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"638A022A-E1D9-162B-E053-F662850A0538","latestVersionIndicator":"Yes","beginDate":"2018-01-24","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-01-24","modifiedBy":"ONEDATA","dateModified":"2018-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"638A022A-E1F1-162B-E053-F662850A0538","beginDate":"2018-01-24","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-01-24","modifiedBy":"ONEDATA","dateModified":"2018-01-24","deletedIndicator":"No"},{"value":"784729","valueDescription":"Ensartinib","ValueMeaning":{"publicId":"6054163","version":"1","preferredName":"Ensartinib","longName":"6054163","preferredDefinition":"784729-Ensartinib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"638A022A-E1FB-162B-E053-F662850A0538","latestVersionIndicator":"Yes","beginDate":"2018-01-24","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-01-24","modifiedBy":"ONEDATA","dateModified":"2018-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"638A022A-E213-162B-E053-F662850A0538","beginDate":"2018-01-24","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-01-24","modifiedBy":"ONEDATA","dateModified":"2018-01-24","deletedIndicator":"No"},{"value":"748727","valueDescription":"Selumetinib","ValueMeaning":{"publicId":"6054164","version":"1","preferredName":"Selumetinib","longName":"6054164","preferredDefinition":"748727-Selumetinib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"638A022A-E21D-162B-E053-F662850A0538","latestVersionIndicator":"Yes","beginDate":"2018-01-24","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-01-24","modifiedBy":"ONEDATA","dateModified":"2018-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"638A022A-E235-162B-E053-F662850A0538","beginDate":"2018-01-24","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-01-24","modifiedBy":"ONEDATA","dateModified":"2018-01-24","deletedIndicator":"No"},{"value":"783668","valueDescription":"LY3023414","ValueMeaning":{"publicId":"6054165","version":"1","preferredName":"LY3023414","longName":"6054165","preferredDefinition":"783668-LY3023414","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"638A022A-E23F-162B-E053-F662850A0538","latestVersionIndicator":"Yes","beginDate":"2018-01-24","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-01-24","modifiedBy":"ONEDATA","dateModified":"2018-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"638A022A-E257-162B-E053-F662850A0538","beginDate":"2018-01-24","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-01-24","modifiedBy":"ONEDATA","dateModified":"2018-01-24","deletedIndicator":"No"},{"value":"791066","valueDescription":"Tazemetostat","ValueMeaning":{"publicId":"6054166","version":"1","preferredName":"Tazemetostat","longName":"6054166","preferredDefinition":"791066-Tazemetostat","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"638A022A-E261-162B-E053-F662850A0538","latestVersionIndicator":"Yes","beginDate":"2018-01-24","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-01-24","modifiedBy":"ONEDATA","dateModified":"2018-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"638A022A-E279-162B-E053-F662850A0538","beginDate":"2018-01-24","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-01-24","modifiedBy":"ONEDATA","dateModified":"2018-01-24","deletedIndicator":"No"},{"value":"781558","valueDescription":"Erdafitinib","ValueMeaning":{"publicId":"6054167","version":"1","preferredName":"Erdafitinib","longName":"6054167","preferredDefinition":"781558-Erdafitinib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"638A022A-E283-162B-E053-F662850A0538","latestVersionIndicator":"Yes","beginDate":"2018-01-24","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-01-24","modifiedBy":"ONEDATA","dateModified":"2018-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"638A022A-E29B-162B-E053-F662850A0538","beginDate":"2018-01-24","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-01-24","modifiedBy":"ONEDATA","dateModified":"2018-01-24","deletedIndicator":"No"},{"value":"788607","valueDescription":"LOXO-101","ValueMeaning":{"publicId":"6054168","version":"1","preferredName":"LOXO-101","longName":"6054168","preferredDefinition":"788607-LOXO-101","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"638A022A-E2A5-162B-E053-F662850A0538","latestVersionIndicator":"Yes","beginDate":"2018-01-24","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-01-24","modifiedBy":"ONEDATA","dateModified":"2018-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"638A022A-E2BD-162B-E053-F662850A0538","beginDate":"2018-01-24","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-01-24","modifiedBy":"ONEDATA","dateModified":"2018-01-24","deletedIndicator":"No"},{"value":"812076","valueDescription":"LOXO-292","ValueMeaning":{"publicId":"7148763","version":"1","preferredName":"LOXO-292","longName":"7148763","preferredDefinition":"812076-LOXO-292","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9CD36448-2D9F-7CF9-E053-F662850A9AA8","latestVersionIndicator":"Yes","beginDate":"2020-01-23","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-01-23","modifiedBy":"ONEDATA","dateModified":"2020-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9CD36448-2DB8-7CF9-E053-F662850A9AA8","beginDate":"2020-01-23","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-01-23","modifiedBy":"ONEDATA","dateModified":"2020-01-23","deletedIndicator":"No"},{"value":"702818","valueDescription":"Tipifarnib","ValueMeaning":{"publicId":"3379529","version":"1","preferredName":"Tipifarnib","longName":"3379529","preferredDefinition":"A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an enzyme involved in protein processing (farnesylation) for signal transduction.  By inhibiting the farnesylation of proteins, this agent prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tipifarnib","conceptCode":"C1703","definition":"A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an enzyme involved in protein processing (farnesylation) for signal transduction.  By inhibiting the farnesylation of proteins, this agent prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-32E0-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9CD36448-2DCC-7CF9-E053-F662850A9AA8","beginDate":"2020-01-23","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-01-23","modifiedBy":"ONEDATA","dateModified":"2020-01-23","deletedIndicator":"No"},{"value":"799018","valueDescription":"Ulixertinib","ValueMeaning":{"publicId":"7148764","version":"1","preferredName":"Ulixertinib","longName":"7148764","preferredDefinition":"799018-Ulixertinib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9CD36448-2DD6-7CF9-E053-F662850A9AA8","latestVersionIndicator":"Yes","beginDate":"2020-01-23","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-01-23","modifiedBy":"ONEDATA","dateModified":"2020-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9CD36448-2DEF-7CF9-E053-F662850A9AA8","beginDate":"2020-01-23","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-01-23","modifiedBy":"ONEDATA","dateModified":"2020-01-23","deletedIndicator":"No"},{"value":"804600","valueDescription":"Ivosidenib","ValueMeaning":{"publicId":"6429532","version":"1","preferredName":"Ivosidenib","longName":"6429532","preferredDefinition":"An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Upon administration, AG-120 specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells. IDH1, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ivosidenib","conceptCode":"C114383","definition":"An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Upon administration, AG-120 specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells. IDH1, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75AC7369-E7A7-1EBD-E053-F662850A1EEE","latestVersionIndicator":"Yes","beginDate":"2018-09-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-12","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9CD36448-2E03-7CF9-E053-F662850A9AA8","beginDate":"2020-01-23","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-01-23","modifiedBy":"ONEDATA","dateModified":"2020-01-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008528","version":"1","preferredName":"Protocol Administration","preferredDefinition":"the management of a research protocol and its case report forms.","longName":"PROT_ADM","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1ECAD41-A932-34B1-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BC8F53A-0962-7871-E050-BB89AD435BF6","latestVersionIndicator":"Yes","beginDate":"2016-09-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-09-05","modifiedBy":"LEEBUMJ","dateModified":"2020-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"},{"publicId":"3303197","version":"1","longName":"Phase 1/Pilot Consortium","context":"COG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"MATCH related agent name","type":"Preferred Question Text","description":"MATCH related agent name","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BC912E7-231B-7BD3-E050-BB89AD43159E","latestVersionIndicator":"Yes","beginDate":"2016-09-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-09-05","modifiedBy":"EDUARDOJ","dateModified":"2017-11-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}